A Powerful Paradigm for Cardiovascular Risk Stratification Using Multiclass, Multi-Label, and Ensemble-Based Machine Learning Paradigms: A Narrative Review
Authors:
- Jasjit S. SuriJasjit S. Suri
- Mrinalini BhagawatiMBMrinalini Bhagawati
- Sudip PaulSPSudip Paul
- Athanasios D. ProtogerouAthanasios D. Protogerou
- Petros P. SfikakisPSPetros P. Sfikakis
- George D. KitasGKGeorge D. Kitas
- Narendra N. KhannaNKNarendra N. Khanna
- Zoltan RuzsaZoltan Ruzsa
- Aditya M. SharmaASAditya M. Sharma
- Sanjay SaxenaSanjay Saxena
- Gavino FaaGFGavino Faa
- John R. LairdJLJohn R. Laird
Open Access
- 16 March 2022
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 12 (3) , 722
Abstract
Background and Motivation: Cardiovascular disease (CVD) causes the highest mortality globally. With escalating healthcare costs, early non-invasive CVD risk assessment is vital. Conventional methods have shown poor performance compared to more recent and fast-evolving Artificial Intelligence (AI) methods. The proposed study reviews the three most recent paradigms for CVD risk assessment, namely multiclass, multi-label, and ensemble-based methods in (i) office-based and (ii) stress-test laboratories. Methods: A total of 265 CVD-based studies were selected using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) model. Due to its popularity and recent development, the study analyzed the above three paradigms using machine learning (ML) frameworks. We review comprehensively these three methods using attributes, such as architecture, applications, pro-and-cons, scientific validation, clinical evaluation, and AI risk-of-bias (RoB) in the CVD framework. These ML techniques were then extended under mobile and cloud-based infrastructure. Findings: Most popular biomarkers used were office-based, laboratory-based, image-based phenotypes, and medication usage. Surrogate carotid scanning for coronary artery risk prediction had shown promising results. Ground truth (GT) selection for AI-based training along with scientific and clinical validation is very important for CVD stratification to avoid RoB. It was observed that the most popular classification paradigm is multiclass followed by the ensemble, and multi-label. The use of deep learning techniques in CVD risk stratification is in a very early stage of development. Mobile and cloud-based AI technologies are more likely to be the future. Conclusions: AI-based methods for CVD risk assessment are most promising and successful. Choice of GT is most vital in AI-based models to prevent the RoB. The amalgamation of image-based strategies with conventional risk factors provides the highest stability when using the three CVD paradigms in non-cloud and cloud-based frameworks.Keywords
This publication has 247 references indexed in Scilit:
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the AdultCanadian Journal of Cardiology, 2013
- Evolutionary Algorithm-Based Classifier Parameter Tuning for Automatic Ovarian Cancer Tissue Characterization and ClassificationUltraschall in der Medizin - European Journal of Ultrasound, 2012
- Non-linear dynamical signal characterization for prediction of defibrillation success through machine learningBMC Medical Informatics and Decision Making, 2012
- Inflammation in AtherosclerosisJACC, 2009
- Epidemiology of Sudden Cardiac Death: Clinical and Research ImplicationsProgress in Cardiovascular Diseases, 2008
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- ML-KNN: A lazy learning approach to multi-label learningPattern Recognition, 2007
- Learning multi-label scene classificationPattern Recognition, 2004
- Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004